US Famotidine Prices Rise 0.67% in June 2026

The Famotidine market in the United States strengthened during the first half of July as higher export quotations from Asia and rising freight rates increased import costs for US buyers. The Famotidine market extended the firm trend established in June, supported by stable pharmaceutical demand and increasing logistics expenses across major shipping routes. Higher transportation costs from Asia to the United States, coupled with elevated export offers from Chinese and Indian suppliers, encouraged Famotidine importers to secure material despite the higher landed costs. Although domestic demand remained largely stable, steady procurement from generic drug manufacturers and healthcare formulators supported market sentiment. Limited spot availability due to longer transit times also contributed to firmer negotiations, allowing suppliers to maintain higher quotations for Famotidine throughout the first half of July.

The Famotidine CIF Houston price continued to move higher during the first half of July after increasing by 0.67% in June, when the market recorded a modest month-on-month gain supported by higher logistics costs and steady pharmaceutical demand. During June, Famotidine prices strengthened as rising freight expenses, longer shipping routes, and precautionary inventory building by US importers lifted import quotations. The continued increase in Asian export offers during early July further raised landed costs, enabling suppliers to maintain firm pricing despite stable production and adequate supply.

Earlier in June, the Famotidine market recorded a modest increase as stable pharmaceutical consumption and gradually rising logistics costs supported prices. Demand from generic drug manufacturers, OTC medicine producers, hospital procurement channels, and formulation companies remained consistent throughout the month. Production at major Indian manufacturing facilities continued without interruption, while feedstock availability remained stable, ensuring sufficient output. However, container freight rates and geopolitical shipping disruptions gradually increased transportation expenses, encouraging Famotidine exporters to revise quotations upward. US Famotidine importers responded by maintaining precautionary inventories, which helped support the Famotidine market during June.

Supply conditions for Famotidine in the first half of July remained generally stable, with no major production disruptions reported across key manufacturing regions. Nevertheless, higher freight costs from Asia to the United States and stronger export quotations continued to increase the landed cost of Famotidine imports. Longer shipping times and elevated logistics expenses limited immediate spot availability, while steady pharmaceutical demand enabled suppliers to maintain firm offers. As a result, the Famotidine market remained well supported despite adequate production capacity.

Looking ahead, analysts expect the Famotidine market to strengthen further during the second half of July as elevated freight costs, firm Asian export quotations, and consistent pharmaceutical demand continue to support pricing. However, future Famotidine market movements will remain dependent on shipping conditions, freight rates, procurement activity, and overall global supply chain developments.